Literature DB >> 15128838

Lack of galactose-alpha-1,3-galactose expression on porcine endothelial cells prevents complement-induced lysis but not direct xenogeneic NK cytotoxicity.

Bettina C Baumann1, Pietro Forte, Robert J Hawley, Robert Rieben, Mårten K J Schneider, Jörg D Seebach.   

Abstract

The galactose-alpha-1,3-galactose (alphaGal) carbohydrate epitope is expressed on porcine, but not human cells, and therefore represents a major target for preformed human anti-pig natural Abs (NAb). Based on results from pig-to-primate animal models, NAb binding to porcine endothelial cells will likely induce complement activation, lysis, and hyperacute rejection in pig-to-human xenotransplantation. Human NK cells may also contribute to innate immune responses against xenografts, either by direct recognition of activating molecules on target cells or by FcgammaRIII-mediated xenogeneic Ab-dependent cellular cytotoxicity (ADCC). The present study addressed the question as to whether the lack of alphaGal protects porcine endothelial cells from NAb/complement-induced lysis, direct xenogeneic NK lysis, NAb-dependent ADCC, and adhesion of human NK cells under shear stress. Homologous recombination, panning, and limiting dilution cloning were used to generate an alphaGal-negative porcine endothelial cell line, PED2*3.51. NAb/complement-induced xenogeneic lysis of PED2*3.51 was reduced by an average of 86% compared with the alphaGal-positive phenotype. PED2*3.51 resisted NK cell-mediated ADCC with a reduction of lysis ranging from 30 to 70%. However, direct xenogeneic lysis of PED2*3.51, mediated either by freshly isolated or IL-2-activated human NK cells or the NK cell line NK92, was not reduced. Furthermore, adhesion of IL-2-activated human NK cells did not rely on alphaGal expression. In conclusion, removal of alphaGal leads to a clear reduction in complement-induced lysis and ADCC, but does not resolve adhesion of NK cells and direct anti-porcine NK cytotoxicity, indicating that alphaGal is not a dominant target for direct human NK cytotoxicity against porcine cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15128838     DOI: 10.4049/jimmunol.172.10.6460

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  23 in total

1.  Rapid biogenesis and sensitization of secretory lysosomes in NK cells mediated by target-cell recognition.

Authors:  Dongfang Liu; Liang Xu; Fan Yang; Dongdong Li; Feili Gong; Tao Xu
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-23       Impact factor: 11.205

2.  Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study.

Authors:  Jeffrey M Hardacre; Mary Mulcahy; William Small; Mark Talamonti; Jennifer Obel; Smitha Krishnamurthi; Caio S Rocha-Lima; Howard Safran; Heinz-Joseph Lenz; E Gabriela Chiorean
Journal:  J Gastrointest Surg       Date:  2012-11-15       Impact factor: 3.452

Review 3.  Genetically-engineered pigs as sources for clinical red blood cell transfusion: What pathobiological barriers need to be overcome?

Authors:  Benjamin Smood; Hidetaka Hara; Leah J Schoel; David K C Cooper
Journal:  Blood Rev       Date:  2019-01-28       Impact factor: 8.250

Review 4.  Immunological challenges and therapies in xenotransplantation.

Authors:  Marta Vadori; Emanuele Cozzi
Journal:  Cold Spring Harb Perspect Med       Date:  2014-04-01       Impact factor: 6.915

Review 5.  Historical Perspective and Future Direction of Blood Vessel Developments.

Authors:  Sashka Dimitrievska; Laura E Niklason
Journal:  Cold Spring Harb Perspect Med       Date:  2018-02-01       Impact factor: 6.915

6.  Complete absence of the αGal xenoantigen and isoglobotrihexosylceramide in α1,3galactosyltransferase knock-out pigs.

Authors:  Gisella L Puga Yung; Yunsen Li; Lubor Borsig; Anne-Laure Millard; Maria B Karpova; Dapeng Zhou; Jörg D Seebach
Journal:  Xenotransplantation       Date:  2012 May-Jun       Impact factor: 3.907

Review 7.  Clinical lung xenotransplantation--what donor genetic modifications may be necessary?

Authors:  David K C Cooper; Burcin Ekser; Christopher Burlak; Mohamed Ezzelarab; Hidetaka Hara; Leela Paris; A Joseph Tector; Carol Phelps; Agnes M Azimzadeh; David Ayares; Simon C Robson; Richard N Pierson
Journal:  Xenotransplantation       Date:  2012 May-Jun       Impact factor: 3.907

Review 8.  Overcoming the barriers to xenotransplantation: prospects for the future.

Authors:  Burcin Ekser; David K C Cooper
Journal:  Expert Rev Clin Immunol       Date:  2010-03       Impact factor: 4.473

9.  Cytokine secretion depends on Galalpha(1,3)Gal expression in a pig-to-human whole blood model.

Authors:  Marit Saethre; Mårten K J Schneider; John D Lambris; Paola Magotti; Guttorm Haraldsen; Jörg D Seebach; Tom E Mollnes
Journal:  J Immunol       Date:  2008-05-01       Impact factor: 5.422

Review 10.  The role of genetically engineered pigs in xenotransplantation research.

Authors:  David K C Cooper; Burcin Ekser; Jagdeece Ramsoondar; Carol Phelps; David Ayares
Journal:  J Pathol       Date:  2015-10-07       Impact factor: 7.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.